State Street’s Citius Pharmaceuticals CTXR Stock Holding History

State Street’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.9K	Hold	23,271	–	–	﹤0.01%	4210
2025 Q4	$18.1K	Hold	23,271	–	–	﹤0.01%	4247
2025 Q3	$28.9K	Hold	23,271	–	–	﹤0.01%	4218
2025 Q2	$37K	Hold	23,271	–	–	﹤0.01%	4139
2025 Q1	$34.7K	Hold	23,271	–	–	﹤0.01%	4141
2024 Q4	$93.1K	Sell	23,271 -1	-0%	-$7	﹤0.01%	4002
2024 Q3	$291K	Hold	23,272	–	–	﹤0.01%	3728
2024 Q2	$340K	Sell	23,272 -65,111	-74%	-$1.17M	﹤0.01%	3661
2024 Q1	$1.98M	Buy	88,383 +89	+0.1%	+$1.63K	﹤0.01%	3282
2023 Q4	$1.67M	Buy	88,294 +192	+0.2%	+$3.64K	﹤0.01%	3364
2023 Q3	$1.51M	Buy	88,102 +3,824	+5%	+$90.9K	﹤0.01%	3426
2023 Q2	$2.53M	Buy	84,278 +65,214	+342%	+$2.15M	﹤0.01%	3304
2023 Q1	$558K	Buy	19,064 +1,360	+8%	+$39.2K	﹤0.01%	3706
2022 Q4	$350K	Hold	17,704	–	–	﹤0.01%	3894
2022 Q3	$536K	Hold	17,704	–	–	﹤0.01%	3751
2022 Q2	$407K	Sell	17,704 -64,959	-79%	-$1.78M	﹤0.01%	3914
2022 Q1	$3.7M	Sell	82,663 -866	-1%	-$34.2K	﹤0.01%	3322
2021 Q4	$3.22M	Sell	83,529 -3,064	-4%	-$139K	﹤0.01%	3461
2021 Q3	$4.39M	Buy	86,593 +7,836	+10%	+$393K	﹤0.01%	3307
2021 Q2	$6.85M	Buy	+78,757	New	+$4.73M	﹤0.01%	3096

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

State Street's CTXR Position: Q1 2026 in Review

State Street held its Citius Pharmaceuticals (CTXR) position steady in Q1 2026 at 23,271 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4210.

State Street first reported a position in CTXR in Q2 2021 and has held it in 20 quarters since. The position peaked at $6.85M in Q2 2021. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

State Street held 23,271 shares of Citius Pharmaceuticals worth $20.9K as of Q1 2026.
State Street left its Citius Pharmaceuticals share count unchanged in Q1 2026.
Citius Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4210 holding.
State Street first reported a position in Citius Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
State Street's Citius Pharmaceuticals position peaked at $6.85M in Q2 2021.
38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.